---
schema_version: "secwatch.filing_event.v1"
accession: "0001104659-26-033885"
form_type: "8-K"
ticker: "FENC"
cik: "0001211583"
company_name: "FENNEC PHARMACEUTICALS INC."
filed_at: "2026-03-24T23:59:59+00:00"
generated_at: "2026-05-15T09:10:04.521791+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.7
calibrated_materiality_score: 0.7
confidence: "high"
source: SEC EDGAR
---

# Fennec posts record FY2025 PEDMARK sales $44.6M (+50% YoY); Q4 $13.8M (+75%)

## Summary
- Full-year net product sales $44.6M vs $29.6M in 2024; Q4 $13.8M vs $7.9M in prior year.
- Net loss $10.1M in FY2025 vs $0.4M in 2024, driven by higher G&A and a $2.0M loss on debt extinguishment.
- Cash $36.7M at year-end; zero debt after paying down $21.5M term loan in Nov 2025.
- Completed oversubscribed equity offerings raising $42.0M net; expanded commercial team.
- Positive topline results from Japan trial; two institution-led studies initiated in testicular cancer and AYA patients.

## SEC filing metadata
- accession: 0001104659-26-033885
- form_type: 8-K
- ticker: FENC
- cik: 0001211583
- company_name: FENNEC PHARMACEUTICALS INC.
- filed_at: 2026-03-24T23:59:59+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.7
- calibrated_materiality_score: 0.7
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1211583/000110465926033885/0001104659-26-033885-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1211583/000110465926033885/fencf-20260324x8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001104659-26-033885
- JSON: https://secwatch.observer/filing/0001104659-26-033885.json
- Plain text: https://secwatch.observer/filing/0001104659-26-033885.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.